Eupatilin (12.5, 25, 50 μmol/L) inhibits the proliferation, metastasis, and spread of prostate cancer cells through modulation of PTEN and NF-κB signaling (Serttas et al., 2021); it blocks the proliferation of esophageal cancer TE1 cells associated with the inhibition of the Akt and ERK pathways (Wang et al., 2018b). Here, NFKB1 is linked to prostate cancer.